Publication | Open Access

Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study

Lymphoid NeoplasiaOncologyMulticenter Feasibility StudyLymphoma PatientsNew Conditioning RegimenPharmacotherapyMedicineRadiation Oncology